Navigation Links
Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
Date:1/12/2009

HAYWARD, Calif., Jan. 12 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that it has completed enrollment in its 500 patient FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) clinical trial designed to examine the impact of varespladib (A-002) when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event.

"We are pleased with the continued progress of our varespladib cardiovascular program targeting secretory phospholipase A2," said Paul Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "The multiple therapeutic impact of varespladib's mechanism of action provides us with a unique opportunity to develop a first-in-class product targeting a life-threatening coronary event for which there are limited therapeutic options."

"With the varespladib trial fully enrolled, we look forward to reporting the biomarker results and event trends later this year," said Colin Hislop, M.D., Senior Vice President of Clinical Development at Anthera Pharmaceuticals, Inc. "Based upon the positive results from varespladib's two previous Phase II clinical trials that demonstrated lipid-lowering and anti- inflammatory benefits, we look forward to examining the impact of varespladib on the hyper-inflammatory state presented by ACS patients."

Anthera's FRANCIS trial is based upon direct feedback from FDA via the Special Protocol Assessment procedure. The trial is designed to assess the impact of oral varespladib on known biological markers of cardiovascular risk. Anthera plans to enroll between 500-700 patients that will be treated for up to six months. The study is being conducted at sites across North America and Europe. The FRANCIS trial is expected to provide further insight into the prevention of secondary Major
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Anthera Pharmaceuticals Forms Scientific Advisory Board
3. Anthera Presents Data on Varespladib at ATVB Meeting
4. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
5. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
6. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
7. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Carrington Completes $8 Million Financing
10. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
11. New Brunswick Scientific Completes Merger Transaction with Eppendorf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., ... banking and therapeutics, announced today that StemCyte has become ... Indy car driven by James Jakes ... IndyCar 2013 season.   StemCyte, Inc. and Rahal ... of umbilical cord blood banking and its educational initiative ...
(Date:5/23/2013)... PI’s new LPS-24 positioners are ... mm travel range with closed-loop sensor resolution up ... these new positioners the ideal choice for high ... version is also available. , More Information: ... be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 , ...
(Date:5/23/2013)... May 23, 2013  Saddleback Memorial Medical Center in ... the first hospital on the West Coast to perform ... surgical option provides women with a state-of-the-art, minimally invasive ... Marc Winter , M.D., a highly regarded ... medical director of minimally invasive surgery at Saddleback Memorial, ...
(Date:5/23/2013)... 23, 2013 BioTrends Research Group, one ... for specialized biopharmaceutical issues, finds that, unaided, one ... specialists reported that in the past six months, ... treatment) in anticipation of the next generation of ... when only 6 percent reported that they had ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... International, LLC,(BioEnergy), a privately-held, biotech-based developer and ... the,acquisition of certain assets of OmniGene Bioproducts, ... employees. OBI, currently based in Cambridge,MA, possesses ... metabolic pathway engineering expertise to develop efficient ...
... to Provide an Attractive Domestic Alternative to ... 18 Fulcrum BioEnergy, Inc.,today announced that ... plans to build one of the first ... to ethanol. The plant will,process municipal solid ...
... China, July 18 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC ... Chinese firm specializing in the manufacture,research, development, ... it has applied for listing approval on ... an important milestone for China-Biotics, and we ...
Cached Biology Technology:BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc. 2BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc. 3Fulcrum BioEnergy Announces Plans to Build One of the First Commercial-Scale Ethanol Plants Using Municipal Solid Waste as Feedstock 2Fulcrum BioEnergy Announces Plans to Build One of the First Commercial-Scale Ethanol Plants Using Municipal Solid Waste as Feedstock 3China-Biotics, Inc. Files Application for Nasdaq Listing 2
(Date:5/23/2013)... Plant Science , Automated conserved ... and promoter evolution among grasses , Within the ... of DNA that undergo little change in position and ... for any proteins. Some of these evolutionarily stable sequences, ... the expression of other genes or the condensation of ...
(Date:5/23/2013)... RICHLAND, Wash. Pacific Northwest National Laboratory honored ... and commercialization of intellectual property at PNNL,s annual ... , The Department of Energy national laboratory ... Year for his work developing battery materials that ... to the electrical grid, and reduce the time ...
(Date:5/23/2013)... of Public Health at Emory University, along with ... received a $4 million grant over four years ... (Health and Exposome Research Center: Understanding Lifetime Exposures). ... awarded in the United States. , The ... of Environmental Health Sciences (NIEHS) of the National ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3
... of the department of genetics, development and cell biology at ... work will be published in the Oct. 12 issue of ... of the green algae chlamydomonas, a single-celled alga that has ... of uses that come out of this, including basic bio-medical ...
... for researching and developing new biopharmaceuticals would be ... of dollars annually, according to a new economic ... and Technology (NIST). , Prepared by RTI ... over the last two decades emphasis in new ...
... project, 115 scientists from around the world report in the ... of data on a tiny green alga called Chlamydomonas, with ... organism that grows in soil and ponds, has approximately 15,000 ... of its genome. Several years ago, they knew less than ...
Cached Biology News:Biopharmaceutical infrastructure key to lower drug development costs 2Study involving more than 100 scientists provides new insights on green algae 2Study involving more than 100 scientists provides new insights on green algae 3Study involving more than 100 scientists provides new insights on green algae 4
... CRE-bla HEK 293T cell line contains the ... cAMP response element (CRE). To obtain the ... into HEK 293T cells by lentivirus. Subsequent ... responsive to forskolin stimulation (Figure 1). The ...
activating transcription factor 4 (tax-responsive enhancer element B67),...
Reactivity: Human...
... of BAC (100+kb), fosmid (40kb), and large ... than any othe BAC vector. On command ... and easy recombinant DNA purification. Available with ... VC) vectors for the highest insert stability. ...
Biology Products: